|
gptkbp:instanceOf
|
gptkb:drug
tetrabenazine derivative
|
|
gptkbp:approvedBy
|
gptkb:FDA
2017
|
|
gptkbp:ATCCode
|
N07XX12
|
|
gptkbp:brand
|
gptkb:Austedo
|
|
gptkbp:CASNumber
|
1392826-25-3
|
|
gptkbp:chemicalFormula
|
C19H21D6NO3
|
|
gptkbp:contraindication
|
hepatic impairment
use with reserpine
use with monoamine oxidase inhibitors
|
|
gptkbp:developer
|
gptkb:Teva_Pharmaceutical_Industries
|
|
gptkbp:eliminationHalfLife
|
9-10 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
deutetrabenazine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
vesicular monoamine transporter 2 (VMAT2) inhibitor
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
323.48 g/mol
|
|
gptkbp:pregnancyCategory
|
Not assigned
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL3989989
DB12020
71722978
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:depression
anxiety
insomnia
somnolence
akathisia
|
|
gptkbp:UNII
|
7S5I7G3JQL
|
|
gptkbp:usedFor
|
treatment of chorea associated with Huntington's disease
treatment of tardive dyskinesia
|
|
gptkbp:bfsParent
|
gptkb:Austedo
|
|
gptkbp:bfsLayer
|
6
|